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Abstract 
 
Hypertrophic cardiomyopathy (HCM) is frequently linked to mutations in the protein 
components of the myosin-containing thick filaments leading to contractile dysfunction and 
ultimately heart failure. However, the molecular structure-function relationships that underlie 
these pathological effects remain largely obscure. Here we chose an example mutation 
(R58Q) in the myosin regulatory light chain (RLC) that is associated with a severe HCM 
phenotype and combined the results from a wide range of in vitro and in situ structural and 
functional studies on isolated protein components, myofibrils and ventricular trabeculae to 
create an extensive map of structure-function relationships. The results can be understood in 
terms of a unifying hypothesis that illuminates both the effects of the mutation and 
physiological signaling pathways. R58Q promotes an OFF state of the thick filaments that 
reduces the number of myosin head domains that are available for actin interaction and ATP 
utilization. Moreover this mutation uncouples two aspects of length-dependent activation 
(LDA), the cellular basis of the Frank-Starling relation that couples cardiac output to venous 
return; R58Q reduces maximum calcium-activated force with no significant effect on 
myofilament calcium sensitivity. Finally, phosphorylation of R58Q RLC to levels that may be 
relevant both physiologically and pathologically restores the regulatory state of the thick 
filament and the effect of sarcomere length on maximum calcium-activated force and thick 
filament structure, as well as increasing calcium sensitivity. We conclude that perturbation of 
thick filament-based regulation may be a common mechanism in the etiology of missense-
mutation-associated HCM, and that this signaling pathway offers a promising target for the 
development of novel therapeutics. 
 
Keywords: myosin; cardiac muscle regulation; myosin regulatory light chain; polarized 
fluorescence; hypertrophic cardiomyopathy 
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1.  Introduction 
 
The cardiac cycle of contraction and relaxation is governed by transient interactions between 
the actin-containing thin and myosin-containing thick filaments, coupled to the hydrolysis of 
ATP [1]. During systole, activation of the thin filaments via calcium binding to troponin 
releases tropomyosin from its blocked position, allowing strong interaction between the 
myosin catalytic domains and their binding sites on actin. Structural re-arrangements in the 
actin-bound catalytic domains, associated with the release of inorganic phosphate from the 
active site, are amplified and transferred via the light chain domain (LCD) to the thick 
filament backbone, leading to nm-scale displacement of the thin filaments towards the center 
of the sarcomere. 
Although calcium binding to and dissociation from the thin filaments are generally regarded 
as the permissive steps allowing myofilament activation and relaxation, respectively, recent 
evidence suggested that the structure of the thick filaments is an important determinant of 
cardiac muscle performance. The concept of a regulatory structural transition in the myosin-
containing thick filaments originated from studies on invertebrate skeletal [2] and mammalian 
smooth muscle [3], but has recently been extended to cardiac muscle. Electron microscopy 
reconstructions of isolated thick filaments from mammalian cardiac muscle suggest that 
myosin heads in the OFF state of the thick filament are folded against their tail domains, 
reducing their availability for actin-binding, ATP hydrolysis and force production [4, 5]. 
Consistent with these structural data, biochemical studies on isolated cardiac muscle 
preparations demonstrated the existence of a pool of myosin heads in a state with ultra-low 
ATPase activity in both relaxing and activating conditions, known as the super-relaxed state 
(SRX) [6]. Regulatory signaling pathways including post-translational modifications of RLC 
[7] and myosin binding protein-C (cMyBP-C) [8], and mechano-sensing [9] have been 
suggested to regulate cardiac muscle function by modulating the myosin OFF or SRX state 
and the number of myosin heads available for contraction.  
Although the molecular details of the protein-protein interactions responsible for the OFF 
state have not been described at the level of high-resolution structures, recent modelling of 
isolated myosin head domain structures into the EM-derived electron density maps suggests 
that the OFF state might be stabilized by conserved interactions between the catalytic 
domains, myosin tails and LCDs of the two-headed myosin molecule [5, 10, 11]. Subsequent 
mapping of myosin missense mutations associated with both hypertrophic and dilated 
cardiomyopathy onto these models suggests that perturbation of intra- and intermolecular 
interactions associated with the OFF state might be involved in the aetiology of these 
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diseases. However, no general paradigm of structure-function relationships for these 
mutations has been established to date. 
The R58Q mutation in the myosin regulatory light chain has frequently been associated with 
a malignant form of familial hypertrophic cardiomyopathy in different patient cohorts [12-14], 
causing early-onset disease and a high incidence of sudden cardiac death. Previous studies 
that attempted to characterize the effects of the R58Q mutation on cardiac muscle function 
have led to somewhat conflicting results in terms of its effect on force development and 
ATPase activity [15-17], most likely associated with the different preparations and 
experimental protocols employed. In vivo analysis of transgenic mouse models expressing 
human RLC carrying the R58Q mutation showed severe diastolic dysfunction [18], 
consistent with the hypertrophic phenotype observed in human gene mutation carriers. 
However, the molecular basis of R58Q’s functional effects has mainly been studied using 
isolated proteins, leading to diverse proposals that cardiac muscle dysfunction might be due 
to decreased calcium binding to RLC [19], altered load-dependent kinetics [20] or decreased 
intrinsic force production by myosin [21]. 
Here we show that the wide range of effects of the R58Q mutation can be understood in 
terms of the structure and regulatory state of the thick filament. We measured structural 
changes in the thick filaments of rat ventricular trabeculae by polarized fluorescence from 
bifunctional rhodamine probes on either wildtype RLC or RLCs containing the R58Q 
mutation, and combined the results from the in situ experiments with biochemical studies of 
isolated myofilament function and protein interactions in vitro. We show that R58Q stabilizes 
the thick filament OFF state associated with reduced contractility and perturbed length-
dependent activation of cardiac myofilaments. We also show that thick filament activation by 
RLC phosphorylation counteracts the effects of the mutation. Because myofilament 
desensitization associated with RLC dephosphorylation has been commonly observed in 
heart failure [22, 23], thick filament activation may offer an attractive new approach for the 
development of heart failure therapeutics. 
 
2.  Materials and Methods 
 
2.1. Reagents 
 
The RLC binding site peptide of the human -cardiac myosin heavy chain encompassing 
amino acids 805-837 (ERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIK) was purchased from 
Peptide Protein Research Ltd. (Fareham, PO15 6DP, UK) (>95% HPLC purity). 
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2.2. Preparation of bifunctional rhodamine labelled RLC and reconstitution into rat 
right ventricular trabeculae 
 
Bifunctional sulforhodamine (BSR) labelled RLCs were prepared as previously described 
[24]. BSR-cRLCs were exchanged into demembranated trabeculae by extraction in CDTA-
rigor solution (composition in mmol/L: 5 CDTA, 50 KCl, 40 Tris-HCl, 0.1% (v/v) Triton X-100, 
pH 8.4) for 30 min followed by reconstitution with 40 mol/L BSR-cRLC in relaxing solution 
for 1 h at 22°C, replacing ~50-70% of the endogenous RLC (see Results). The average 
maximum calcium activated force after reconstitution with WT-BSR-cRLC-E was 87 ± 3% 
(mean ± SEM, n=16) of that before RLC exchange.  
 
2.3. Fluorescence polarization experiments 
 
Activation protocols and composition of experimental solutions were identical to those 
described previously for fluorescence polarization experiments [24, 25]. Polarized 
fluorescence intensities were measured as described previously for skeletal and cardiac 
muscle fibres [25, 26]. Trabeculae were mounted between a strain gauge force transducer 
(KRONEX, Oakland, California 94602, USA; model A-801, resonance frequency ~2 kHz) 
and motor (Aurora Scientific, Dublin, D6WY006, Ireland; Model 312C). Fluorescence 
emission from WT-BSR-cRLC-E and R58Q-BSR-cRLC-E in trabeculae was collected by a 
0.25 N.A. objective using an excitation light beam in line with the emission path. The 
polarization of the excitation and emitted beams was set either parallel or perpendicular to 
the trabecular axis, allowing determination of the order parameter <P2> that describes the 
dipole orientations in the trabeculae [27]. The sarcomere length of trabeculae was measured 
by laser diffraction in relaxing solution prior to each activation. Activating solution contained 
(in mmol/L): 25 imidazole, 15 Na2CrP, 58.7 KPr, 5.65 Na2ATP, 6.3 MgCl2, 10 CaCl2, 10 
K2EGTA, 1 DTT, pH 7.1. Each activation was preceded by a 2-min incubation in pre-
activating solution (composition in mmol/L: 25 imidazole, 15 Na2CrP, 108.2 KPr, 5.65 
Na2ATP, 6.3 MgCl2, 0.2 K2EGTA, 1 DTT, pH 7.1). Solutions with varying concentrations of 
free [Ca2+] were prepared by mixing relaxing and activating solutions using MAXCHELATOR 
software (maxchelator.stanford.edu). Isometric force and steady-state fluorescence 
polarization values were measured once steady force had been established. The 
dependence of force and order parameters on free calcium concentration was fitted to data 
from individual trabeculae using non-linear least-squares regression to the modified Hill 
equation: 
 
F = Y0+A×([Ca
2+]nH/(-log10[pCa50]
nH + [Ca2+]nH)) 
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where pCa50 is the negative logarithm of [Ca
2+] corresponding to half-maximal change in F, 
nH is the Hill coefficient, Y0 is the baseline, and A is the amplitude (for normalized force data: 
Y0=0 and A=1). Trabeculae which showed a decline in maximal calcium activated force of 
more than 15% after the pCa titrations were discarded.  
The rate of force re-development was measured by a fast release and re-stretch protocol 
[28]. Briefly, isometrically contracting trabeculae were released by 20% of their initial length 
(~500 s step response), held at the new length for ~30 ms, and re-stretched to the original 
length. The timecourse of force redevelopment was fitted to a single exponential, yielding the 
rate constant ktr. 
 
2.4. Preparation of cardiac myofibrils and ATPase activity measurements 
 
Cardiac myofibrils (CMFs) were prepared by homogenising freshly frozen ventricular tissue 
samples in myofibril buffer (composition in mmol/L: 20 imidazole, 75 KCl, 2 MgCl2, 2 EDTA, 
1 DTT, 1% (v/v) Triton X-100, pH 7.4, protease inhibitor cocktail (ROCHE Diagnostics Ltd, 
RH15 9RY, United Kingdom), PhosStop cocktail (ROCHE)) followed by centrifugation at 
5,000 g for 5 min at 4°C. CMFs were washed and homogenised three more times in the 
same buffer without Triton X-100. Endogenous RLCs were extracted from CMFs and 
reconstituted with recombinant proteins as described previously [19]. For ATPase 
measurements CMFs were washed three times in ATPase assay buffer (composition in 
mmol/L: 20 MOPS, 35 NaCl, 5 MgCl2, 1 EGTA, 1 DTT, pH 7.0) with varying concentrations 
of CaCl2 (pCa 9 to pCa 4.3) and the CMF concentration adjusted to 0.5 mg/ml. Reactions 
were started by the addition of 2.5 mmol/L ATP and samples taken at the indicated time 
points were quenched with 0.5 volumes ice cold 25% (w/v) TCA solution. Samples were kept 
on ice at all times, diluted with double-deionized water and inorganic phosphate content 
measured using the malachite green assay according to manufacturer’s instructions 
(SIGMA, GILLINGHAM SP8 4XT, United Kingdom; MAK030). 
 
2.5. RLC Phosphorylation in vitro and in situ 
 
In vitro kinase assays for RLCs were performed in cMLCK assay buffer (composition in 
mmol/L: 25 HEPES, 50 NaCl, 2 MgCl2, 1 CaCl2, 2 DTT, 1 ATP, pH 7) in a total volume of 50 
l containing 0.5 mg/ml (~25 mol/L) RLC as substrate. Calmodulin was added to a final 
concentration of 6 g/ml. The reactions were started by adding the C‐terminal fragment of 
cMLCK to a final concentration of 0.2 mol/L. The reactions were incubated for 30 min at 
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30°C, quenched with 5× sample buffer containing 10 M urea, and analyzed by urea-glycerol-
PAGE. 
RLC-exchanged cardiac myofibrils (0.5 mg/ml) were phosphorylated in situ in activating 
solution (pCa 4.3) containing 25 mol/L Blebbistatin and 6 g/ml calmodulin. Reactions were 
started by addition of cMLCK fragment to a final concentration of 0.2 mol/L and incubated 
at 30°C. Samples were taken at the indicated time points, myofibrils harvested by 
centrifugation and solubilized in SDS-PAGE loading buffer. RLCs were phosphorylated in 
demembranated trabeculae as previously described [7]. Briefly, trabeculae were incubated in 
relaxing buffer (pCa 9) containing 30 mmol/L 2,3-butadione monoxime (BDM), washed in 
activating solution (pCa 4.3) containing 30 mmol/L BDM and then incubated in activating 
solution (pCa 4.3) containing 30 mmol/L BDM, 1 mol/L cMLCK and 1 mol/L CaM. After 1 
h, BDM, cMLCK and CaM were removed from the trabeculae by three washes in relaxing 
solution for 10 min. RLC phosphorylation levels were analyzed by PhostagTM-SDS-PAGE 
followed by Western blot against RLC as described previously [7]. 
 
2.6. Reconstitution of recombinant RLCs into isolated -cardiac myosin, and F-
actin activated ATPase measurements 
 
Isolated porcine -cardiac myosin (Cytoskeleton Inc., Denver, CO 80223, USA; MYO3-A) 
was depleted of its endogenous RLCs and reconstituted with recombinant RLCs as 
described previously [21]. Rabbit skeletal actin was purchased from Sigma (A2522), and 
further purified by de-polymerization in general actin buffer (composition in mmol/L: 5 Tris-
HCl, 0.2 CaCl2, 0.2 ATP, 0.5 DTT, pH 8.0) followed by centrifugation at 15,000g for 15 min 
at 4°C. F-actin was re-polymerized by addition of 10% (v/v) polymerization buffer 
(composition in mmol/L: 500 KCl, 20 MgCl2, 10 ATP) for 1 h at 22°C.  F-actin was pelleted 
by centrifugation at 100,000g for 1 h at 4°C and re-suspended in assay buffer for ATPase 
measurements. As a control, pre-formed F-actin filaments were purchased from 
Cytoskeleton Inc. (AKF99). Both F-actin preparations gave identical results. F-actin activated 
ATPase activity of RLC-exchanged myosin (0.1 mg/ml final concentration) was measured in 
25 mmol/L imidazole pH 7.0, 3 mmol/L MgCl2, 30 mmol/L KCl and 1 mmol/L DTT. Reactions 
were started by adding 2.5 mmol/L ATP and incubated for 30 min at 30°C. Reactions were 
quenched with 0.5 volumes of ice cold 25% (w/v) TCA, diluted with ddH2O and debris 
removed by centrifugation at 15,000g for 30 min. The rate of phosphate release was 
measured with the malachite green method as described previously [29]. 
 
2.7. Microscale Thermophoresis 
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Microscale thermophoresis experiments were performed on a Monolith NT.115 instrument 
(NanoTemper, Cambridge CB3 0AX, United Kingdom) in interaction buffer containing 20 
mmol/L MOPS pH 7, 1 mmol/L MgCl2, 50 mmol/L KCl, 1 mmol/L DTT and 0.05% (v/v) 
Tween-20. WT- and R58Q-RLCs were labelled with Alexa 647-NHS (Molecular Probes Inc, 
Thermo Fischer Scientific, Paisley, PA4 9RF, United Kingdom) according to manufacturer’s 
instructions, and dye incorporation confirmed by HPLC and ESI-mass spectrometry. All 
proteins were either gel-filtered into and/or extensively dialysed against interaction buffer. 
Titration experiments were performed with a fixed Alexa 647 - RLC concentration of 200 
nmol/L in standard treated capillaries. 
 
3. Results 
 
3.1. R58Q stabilizes the OFF conformation of the myosin heads 
 
We used polarized fluorescence from a bifunctional sulforhodamine (BSR) probe attached to 
the RLC E-helix (Fig. 1A) to determine the effects of the R58Q mutation on myosin head 
conformation in demembranated rat right ventricular trabeculae with an endogenously low 
level of RLC phosphorylation (<0.05 mol Pi/mol RLC) [30]. The E-helix labelling site in the C-
lobe was chosen to avoid any direct effects of probe attachment and R58Q mutation on the 
structure of the N-lobe. The RLC E-helix is roughly parallel to the myosin lever arm, and 
provides a sensitive and reproducible signal for the orientation of the RLC-region of myosin 
with respect to the thick filament axis. BSR-RLCs were introduced into demembranated 
trabeculae by an extraction-reconstitution protocol (see Materials and Methods), replacing 
69 ± 3% (mean ± SEM, n=5) of the native RLCs as estimated by SDS-PAGE and Western 
blot against RLC (Fig. S1A). Localization of BSR-labelled R58Q-RLCs to the sarcomeric A-
band was confirmed by counter-stain against myosin heavy chain and confocal microscopy 
(Fig. S1B). Polarized fluorescence intensities were used to calculate the order parameter 
<P2>, which is equal to +1 if the E-helix is parallel to the thick filament axis and -0.5 if it is 
perpendicular (Fig. 1A).  
<P2> for the wildtype RLC E-helix probe (WT-BSR-cRLC-E) is reduced from ~0.25 to ~0.16 
on calcium activation of ventricular trabeculae (Fig. 1B), indicating a more perpendicular 
orientation of the myosin heads with respect to the thick filament, consistent with previous 
results [29]. <P2> for the E-helix probe was significantly higher for R58Q than wildtype RLC, 
both during relaxing conditions (REL, pCa 9) and full calcium activation (ACT, pCa 4.3), 
suggesting that the R58Q mutation induces a more parallel orientation of the RLC-region of 
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the myosin heads in both conditions. Moreover, the effect was significantly larger for full 
calcium activation. The decrease in <P2> associated with full calcium activation (<P2>), a 
measure of the extent of calcium-dependent thick filament activation (Fig. S2), was ~30% 
smaller in trabeculae exchanged with R58Q-BSR-cRLC-E (Fig. 1C). 
These effects of the R58Q mutation on myosin head conformation were accompanied by 
functional changes. Although there was no significant effect on the ATPase activity of 
cardiac myofibrils in relaxing conditions, replacement of 30-40% of endogenous rat 
ventricular RLC by R58Q-RLC in freshly prepared cardiomyofibrils (CMFs) (Fig. S3) reduced 
maximal calcium-activated ATPase activity by ~20% with respect to control CMFs 
exchanged with unlabeled WT-RLC (Fig. 1D), as expected from the more OFF orientation of 
the myosin head domain inferred from the E-helix probe orientation. The R58Q mutation 
reduced maximum Ca2+-activated isometric force of ventricular trabeculae by a similar extent 
(~30%) (Fig. 1E). The rate of force redevelopment (ktr) following a fast release-stretch 
protocol [28] at full calcium activation was reduced by ~15% with respect to the WT control 
(Fig. 1F), indicating slower cross-bridge kinetics in the presence of the mutation.  
In summary, the R58Q mutation promotes the OFF conformation of the myosin heads on the 
thick filament, and reduces isometric force, the rate of force redevelopment and myofibrillar 
ATPase. 
 
3.2. Effects of the R58Q mutation on isolated cardiac myosin and RLC 
 
As a step towards dissecting the molecular mechanism of R58Q’s effect on myosin head 
conformation, we measured the affinity of unlabeled WT- and R58Q-RLC for the cardiac 
myosin heavy chain (MHC). About 70% of the native RLC was extracted from isolated 
porcine -cardiac myosin and the depleted myosin reconstituted with different mole fractions 
of either WT- or R58Q-RLC. The Kd for RLC binding was estimated as ~4 mol/L for both 
RLCs by densitometric analysis using the ELC as an internal loading control, in agreement 
with previous results [31], suggesting that R58Q does not affect the RLC-MHC interaction 
(Fig. S4A). We also titrated a short MHC peptide corresponding to the RLC binding site 
against either WT or R58Q-RLC and found that tryptophan fluorescence from the peptide 
increased by about 80% upon RLC binding for both WT and R58Q (Fig. S4B). This result 
suggests that the tryptophan residues are in a similar chemical environment, but the 
apparent dissociation constant for the RLC-MHC peptide complex was too low (<0.5 mol/L) 
to be measured reliably using this approach. 
We further assessed the effect of the RLC R58Q mutation on the function of isolated myosin 
by steady-state acto-myosin ATPase measurements. RLC depleted -cardiac myosin was 
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fully reconstituted with either WT- or R58Q-RLC, or a mixture of both (Fig. 2A), and the 
dependence of the myosin ATPase activity on the F-actin concentration fitted to the 
Michaelis-Menten equation (Fig. 2B). Vmax did not significantly differ among the three groups 
(~6 s-1 head-1), but KM increased from 1.50 ± 0.08 mol/L (mean ± SEM, n=3) for myosin 
exchanged with WT-RLC to 2.91 ± 0.06 mol/L for myosin exchanged with R58Q-RLC, 
suggesting that the R58Q mutation decreases the probability of actin-myosin interaction in 
vitro. Myosin exchanged with a mixture of WT- and R58Q-RLC showed an intermediate 
value of KM. These results are consistent with the in situ experiments in demembranated 
trabeculae, giving further support for the conclusion that R58Q stabilizes the OFF 
conformation of the myosin molecule. The effect of the R58Q mutation on RLC stability was 
assessed by Microscale Thermophoresis (MST) in the presence of increasing concentrations 
of guanidine hydrochloride (GdnHCl) (Fig. 2C; Fig. S5A). Both Alexa 647 labeled WT- and 
R58Q-RLCs showed a biphasic unfolding behavior, with the MST signal decreasing between 
0 mol/L and 3 mol/L GdnHCl before increasing again at [GdnHCl] > 3 mol/L. Although the 
thermophoretic mobilities of the two RLCs in the presence of 8 mol/L GdnHCl were 
indistinguishable, the MST signal of R58Q-RLC in the absence of GdnHCl was significantly 
larger than that of WT-RLC suggesting a different protein conformation. Data points between 
0 and 3 mol/L GdnHCl were fitted to a Hill equation resulting in Hill coefficients >2, 
suggesting a cooperative unfolding mechanism, with EC50 values of 1.28 ± 0.11 mol/L (mean 
± SEM, n=3) and 0.79 ± 0.10 mol/L for WT-RLC and R58Q-RLC, respectively, indicating 
lower RLC stability in the presence of R58Q. 
RLC can also bind to N-terminal domains of cardiac myosin binding protein-C (cMyBP-C) 
[10, 32] and this interaction may influence the conformation of the myosin heads in native 
thick filaments. We therefore determined the affinity of both the WT- and R58Q-RLC for 
different domains of cMyBP-C using MST (Fig. 2D and Fig. S5B). Isolated WT-RLC binds to 
a cMyBP-C fragment spanning domains C0 to C2 (C0C2) with a Kd of 8.6 ± 0.1 mol/L 
(mean ± SEM, n=6), but does not interact with a fragment of the central domains (C3C5), 
suggesting a specific interaction with the N-terminus of cMyBP-C. The isolated RLC retained 
an interaction with C0C2 in the presence of the R58Q mutation, albeit with a slightly 
decreased affinity (Kd of 9.7 ± 0.7 mol/L, n=4). 
 
3.3. R58Q perturbs the effect of sarcomere length on maximum force but not that 
on calcium sensitivity 
 
Since changes in the conformation of the myosin heads may be involved in length-
dependent activation (LDA) in cardiac muscle and the Frank-Starling Law of the heart [7, 33, 
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34], and impaired LDA has been linked to heart failure associated with sarcomeric protein 
missense mutations [35], we investigated the effect of the R58Q mutation on the change in 
myosin head conformation associated with LDA. 
Ventricular trabeculae were exchanged with either WT- or R58Q-BSR-cRLC-E, and the 
[Ca
2+
]-dependence of force development and myosin head orientation determined at short 
(~1.9 m) and long (~2.2 m) sarcomere lengths (Fig. 3; Table S1). Both WT- and R58Q-
BSR-cRLC-E exchanged trabeculae showed a significant increase in the calcium sensitivity 
of force on increasing sarcomere length (SL). The calcium concentration corresponding to 
half-maximal force (pCa50) increased by 0.11 ± 0.01 and 0.12 ± 0.02 pCa units (mean ± 
SEM, n = 4-7) for the WT and R58Q groups, respectively, indicating that the R58Q mutation 
had no detectable effect on the increase in myocardial calcium sensitivity with increase in 
sarcomere length (Figs. 3A and 3B; Table S1).  
Both passive (measured at pCa 6.4) and active force (measured at pCa 4.3) significantly 
increased with increasing sarcomere length in trabeculae exchanged with WT-BSR-cRLC-E 
(Fig. 3C). Active isometric force increased by ~25%, from 34.8 ± 2.3 to 43.6 ± 4.4 mN/mm2 
(mean ± SEM, n=6). However, the length-dependence of active force was almost abolished 
in the presence of R58Q-RLC (it was only ~6%, from 26.9 ± 2.6 to 28.9 ± 2.9 mN/mm2). 
Passive force at each sarcomere length was the same in the WT and R58Q groups (Fig. 3D; 
Table S1).  
Increasing SL from 1.9 to 2.2 m increased <P2> and the calcium sensitivity of the <P2>-pCa 
relation by 0.14 ± 0.04 and 0.13 ± 0.02 pCa units for WT- and R58Q-BSR-cRLC-E 
exchanged trabeculae, respectively (Figs. 3E and F; Table S1). Moreover, the effect of the 
R58Q mutation on the orientation of the myosin head domains in relaxing conditions is 
smaller at longer sarcomere length. However, the amplitude of the structural change 
associated with activation (<P2>) was almost independent of SL in the presence of R58Q, 
in contrast with the ~24% change in the WT group. These effects on the structure of the 
thick filament are strikingly similar to those on active isometric force, suggesting that the 
higher active force at the longer SL is associated with a more ON structure of the thick 
filament [34], and that both effects are abolished by the R58Q mutation.  
 
3.4. RLC phosphorylation increases active force and restores the effect of SL on 
active force in R58Q-RLC exchanged trabeculae 
 
RLC phosphorylation increases the contractility of cardiac muscle by promoting the thick 
filament ‘ON’ state characterized by a more perpendicular orientation of the myosin heads 
with respect to the thick filament axis [7, 30]. Since these effects are in the opposite direction 
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to those produced by the R58Q mutation, we hypothesized that phosphorylation of RLC 
might restore myosin conformation and function in R58Q-RLC exchanged trabeculae.  
First we used an expressed cardiac myosin light chain kinase (cMLCK) to determine whether 
the R58Q mutation interferes with RLC phosphorylation. Both WT- and R58Q-RLCs could be 
fully phosphorylated by cMLCK in vitro (Fig. 4A), consistent with previously published results 
using smooth muscle MLCK [19]. Next we measured the time course of in situ 
phosphorylation of RLCs in cardiac myofibrils containing ~50% of either WT- or R58Q-RLC 
(Fig. 4B). In contrast to trabeculae, myofilaments in CMFs are directly accessible by the 
kinase and allows direct comparison of the rate of RLC phosphorylation. RLCs in both 
groups could be phosphorylated to over 90% within 90 min with a similar time course (Fig. 
4C), confirming the results with isolated RLCs. Double exponential fitting suggested that 
these phosphorylation time courses have slow and fast components of almost equal 
amplitude. Control experiments with native untreated CMFs showed only the slow 
component (Fig. 4C, triangles), perhaps indicating selectivity of the human cMLCK for 
human RLCs.  
Incubation of RLC-exchanged trabeculae with Ca2+/CaM/cMLCK for 1 h increased the in situ 
phosphorylation level of exchanged R58Q-BSR-cRLC-E and total RLCs to 0.27 ± 0.03 mol 
Pi/mol RLC and 0.29 ± 0.04 mol Pi/mol RLC (mean SEM, n=7) respectively, indicating that 
native rat and R58Q-BSR-cRLC-E were phosphorylated equally by cMLCK (Fig. S6). 
Consistent with our previous study using a BSR probe attached to the RLC N-lobe [7], RLC 
phosphorylation to ~0.3 mol Pi/mol RLC (Fig. S6)  of R58Q-BSR-cRLC-E exchanged 
trabeculae increased the calcium sensitivity of force by ~0.07 pCa units (Fig. S7A) and 
increased maximum active isometric force by ~30%, from ~24 to ~31 mN/mm
2
. The latter 
value is close to that of WT-BSR-cRLC-E exchanged trabeculae in the RLC 
dephosphorylated state at the same sarcomere length (Fig. 4D, dotted line). 
Phosphorylation of RLC to ~0.3 mol Pi/mol RLC (Fig. S6) by cMLCK also increased the 
extent of calcium-induced activation of the thick filament as measured by <P2> from the 
RLC E-helix probe, to values close to those obtained for unphosphorylated WT-BSR-cRLC-E 
(Fig. 4E, dotted lines), and increased the rate of force redevelopment (kTR) from ~12 s
-1 to 
~18 s-1 (compared to ~14 s-1 for WT BSR-cRLC-E) (Fig. 4F). These results indicate that RLC 
phosphorylation restores cardiac contractility and the regulatory state of the thick filament in 
the presence of the R58Q mutation. 
Incubation of R58Q-RLC exchanged trabeculae with cMLCK also restored the dependence 
of maximum active force on sarcomere length. Maximum active force of R58Q-BSR-cRLC-E 
exchanged trabeculae after RLC phosphorylation to ~0.3 mol Pi/mol RLC (Fig. S6)  
increased by ~28% on increasing sarcomere length from 1.9 to 2.2 m (compared to only 
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~6% before RLC phosphorylation), similar to the ~25% increase observed for 
unphosphorylated WT-BSR-cRLC-E (Fig. 4D, dotted lines). RLC phosphorylation preserved 
the increase in calcium sensitivity of force associated with LDA (pCa50 of ~0.1), but 
decreased the Hill coefficient of the force-calcium relation from ~6 to ~4 (Fig. S7B), as 
reported previously [7]. Similar to the effects on maximum active force, <P2> measured 
from R58Q-BSR-cRLC-E increased by ~20% on sarcomere stretch in the presence of 
phosphorylated RLCs (Fig. 4E) indicating a higher fraction of heads in the perpendicular 
orientation. In summary, RLC phosphorylation counteracts the effects of R58Q on thick 
filament activation and force development, and restores the regulatory state of the thick 
filament in the presence of this mutation. 
 
4. Discussion 
 
4.1. RLC R58Q stabilizes the OFF state of the thick filament 
 
The present results suggest that the HCM-associated mutation R58Q in the myosin RLC 
disrupts the function of cardiac muscle by interfering with the thick filament-based regulatory 
system that operates in parallel with the canonical calcium/thin filament system (Fig. 5). In 
situ fluorescence polarization measurements from a bifunctional probe on the E-helix of the 
RLC in ventricular trabeculae indicated a more parallel orientation of the myosin head 
domains with respect to the thick filament in the presence of R58Q, as shown by a higher 
value of the order parameter <P2> in relaxing conditions, although the effect is diminished at 
long sarcomere length. This higher value of <P2> for the E-helix probe is characteristic of the 
‘interacting heads motif’ (IHM) conformation of myosin associated with the OFF state of the 
thick filament (Fig. 1A). 
The R58Q mutation also reduced the changes in orientation of the RLC-region of the myosin 
heads on calcium activation that are associated with release of myosin heads from the 
parallel or OFF state close to the surface of thick filament, indicating that a smaller fraction of 
myosin heads are available for actin binding and force generation in the presence of the 
mutation. Active force and ATP utilization were reduced to a similar extent [16] as this 
structural signal, indicating that the R58Q mutation acts by decreasing the number of myosin 
motors available for contraction rather than by altering motor function per se. 
The RLC region of the myosin head is involved in many different molecular interactions in 
the sarcomere, and the present results help to clarify which of these interactions are 
perturbed by the R58Q mutation. In contrast with previous suggestions that a loss of 
regulatory interactions between myosin and cMyBP-C might be associated with the 
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development of HCM [10, 32, 36], we found no effect of the R58Q mutation on the affinity of 
isolated RLC for the N-terminal domains of cMyBP-C (Fig. 2D).  We also found that the high 
cooperativity of thick filament calcium activation indicated by a Hill coefficient of around 7 for 
the <P2>-pCa relation is preserved in the presence of the mutation (Table S1), indicating that 
cooperative interactions between myosin heads in the OFF state are not affected by R58Q. 
The affinity of RLC for cardiac -myosin is also not affected by the R58Q mutation (Fig. 
S4A), suggesting that the interactions between the RLC and the myosin heavy chain and 
ELC are preserved. The R58Q mutation does not affect the maximal acto-myosin ATPase 
activity, although it reduces the KM, consistent with the in situ indication that fewer myosin 
heads are available for actin interaction, but the properties of the available heads are 
normal. 
On the basis of the present results, the most likely molecular interpretation for the effects of 
the R58Q mutation would seem to be disruption of intra-molecular interactions within the 
myosin molecule. R58Q alters the conformation of isolated RLC, destabilizing its tertiary fold 
(Fig. 2C). These changes could perturb interactions between the two light chain domains of 
individual myosin molecules, or between its head and tail domains. Since the folded OFF 
state has also been observed for isolated cardiac myosin [37], such a mechanism might also 
explain the reduced force and power output of isolated R58Q-RLC exchanged cardiac 
myosin [20, 21]. Our previous fluorescence polarization studies demonstrating distinct 
conformations of the RLC N- and C-lobes in relaxed and active cardiac muscle [24] are also 
consistent with this type of mechanism, in which flexibility within the RLC is required for the 
regulatory transition in myosin. The location of the RLC N-lobe at the junction between the 
two myosin heads with the tail is well-placed to control regulatory changes in the 
conformation of the myosin head domains [30].  
 
4.2. R58Q perturbs the effect of sarcomere length on maximum force but preserves 
its effect on calcium sensitivity 
 
The molecular mechanisms underlying the Frank-Starling Law of the heart and its cellular 
analogue, length-dependent activation (LDA), remain poorly understood. Recently it has 
been suggested that thick filament regulation may play a role in LDA, i.e. that a more ON 
state of the thick filament at longer sarcomere length might make more myosin heads 
available for actin interaction [7, 9, 33]. Specifically, increased sarcomere length generates 
mechanical stress that is communicated to the thick filament by the titin links between the 
tips of the thick filaments and the ends of the sarcomere, which switches the thick filaments 
ON by a direct mechano-sensing mechanism [7, 9, 38]. This transition in the thick filaments 
might then be communicated to the thin filaments by some unknown mechanism. It has also 
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been suggested that two aspects of LDA, the higher force at maximal calcium activation and 
the change in calcium sensitivity at submaximal calcium, might be mediated by different 
mechanisms [34], with the former being most directly linked to the regulatory state of the 
thick filament.  
Consistent with that hypothesis, we found that the RLC R58Q mutation had no effect on the 
sarcomere length-dependence of passive force or the calcium sensitivity of active force, but 
almost abolished the sarcomere length-dependence of maximum force (Fig. 3). The same 
distinction between these two aspects of LDA was observed for the regulatory state of the 
thick filament as reported by the RLC E-helix probe. In terms of the mechano-sensing 
hypothesis of thick filament regulation, additional passive stress is still transmitted to the 
thick filaments at longer sarcomere length in the presence of the R58Q mutation, but no 
longer leads to more myosin heads being released from the thick filament backbone. Thus 
the R58Q mutation seems to uncouple thick filament stress from its regulatory state, 
although the effect of sarcomere length on calcium sensitivity is retained, presumably 
because it is mediated by a separate signaling pathway that links the regulatory states of the 
thick and thin filaments [33, 34].  
The present results further suggest that inter-filament signaling is not mediated by the 
number of myosin heads available for thin filament binding [33, 34], since this number 
becomes almost independent of sarcomere length in the presence of the R58Q mutation. It 
seems more likely that that inter-filament signaling is mediated by cMyBP-C [24]. The N-
terminal domains of cMyBP-C have competing binding sites for both myosin and actin, and 
N-terminal fragments of cMyBP-C increase the calcium sensitivity of the thin filament in the 
absence of strong binding myosin heads [24]. Moreover, since the C-terminus of cMyBP-C 
binds to both the myosin tail and titin, cMyBP-C is ideally positioned to couple the regulatory 
states of the thick and thin filaments. 
 
4.3. RLC phosphorylation counteracts the effects of the R58Q mutation 
 
The effects of the R58Q mutation on cardiac contractility described above can be 
counteracted by RLC phosphorylation. R58Q stabilizes the OFF state of the thick filament 
and the parallel IHM conformation of the myosin heads and decreases contractility, whereas 
RLC phosphorylation disrupts the OFF state [7, 10, 30], promotes the ON conformation of 
the thick filament and increases contractility (Fig. 5). RLC phosphorylation has also been 
proposed to enhance the function of isolated myosin by increasing either motor stiffness [21] 
or step size [39]. In terms of thick filament regulatory mechanisms, the antagonistic effects of 
RLC phosphorylation and R58Q may be related to the role of the RLC region of the myosin 
heads to control intra-molecular interactions between the two heads of a myosin molecule, 
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and between the heads and the tail domain [10], as discussed in section 4.1. RLC 
phosphorylation also restores the sarcomere-length dependence of both active force and the 
regulatory state of the thick filament in the presence of the R58Q mutation (Fig. 4D,E), 
presumably by counteracting the stabilization of the OFF state induced by the mutation. 
cMyBP-C phosphorylation may be able to introduce additional functional effects by 
perturbing the same signaling pathways [40] through the mechanisms proposed in section 
4.2, and we have previously shown that cMyBP-C is highly phosphorylated in 
demembranated trabeculae [24]. 
 
4.4. Clinical perspective 
 
Although hypertrophic cardiomyopathy mutations are generally associated with hyper-
contractility [41], usually associated with an increase in myocardial calcium sensitivity, the 
R58Q mutation in RLC decreases contractility by stabilizing the OFF state of the thick 
filament, which may replicate functional defects in early stages of disease development 
before the clinical manifestation of HCM. Consistent with this hypothesis, decreased cardiac 
power, output and efficiency has been observed in isolated perfused working hearts from a 
transgenic mouse model expressing R58Q-RLC [18]. Decreased contractility might lead to 
HCM by increasing the energy cost of contraction followed by pathogenic remodeling of the 
heart [42, 43], or via hypertrophy acting as a direct compensatory mechanism [44] in later 
stages of disease progression. It has been suggested that altered phosphorylation of 
myofilament regulatory proteins could be responsible for the increased calcium sensitivity 
observed in end-stage heart failure [22], and restoration of phosphorylation levels by an 
exogenous kinase restored myofilament calcium sensitivity [35], suggesting that hypo-
phosphorylation of protein targets and not missense mutations per se are responsible for the 
hyper-contractile phenotype normally associated with HCM. Alternatively, perturbed LDA 
and mechano-sensing have been implicated as common mechanisms that may contribute to 
cardiac dysfunction observed in missense gene mutation carriers [35]. Consistent with that 
hypothesis, the HCM-associated mutation R58Q decreases contractility and sarcomere-
length dependent myofilament activation in a RLC phosphorylation-dependent manner. 
Moreover, reduced levels of RLC phosphorylation have been found in both human end-stage 
failing myocardium [22], and myocardium from a transgenic mouse model carrying the RLC-
R58Q mutation [18], suggesting that RLC dephosphorylation further contributes to cardiac 
dysfunction and remodeling.  
Modulation of cardiac myosin function is a promising route for the development of novel 
heart failure therapeutics, and much effort has been directed towards the development of 
small molecule effectors that directly target the myosin head domain [45, 46]. An alternative 
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approach, however, would be to modulate the function of cardiac myosin by targeting the 
normal signaling pathways that control thick filament structure. RLC phosphorylation has 
been shown to be an important determinant of cardiac muscle function in both health and 
disease [47, 48], and pseudo-phosphorylation of RLC in mouse models carrying sarcomeric 
protein missense mutations prevents the clinical onset of HCM [49]. Consistent with these 
observations, increasing the RLC phosphorylation level in our experiments significantly 
increased contractility and improved LDA in the presence of the R58Q mutation. Although 
the signaling pathways upstream of cMLCK are incompletely understood, it may be possible 
to identify small molecules that specifically activate cMLCK, increase contractility and 
counteract the development of HCM-associated heart failure. 
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Figure Legends 
 
Figure 1. R58Q stabilizes the OFF conformation of the myosin heads. (A) Left: 
Structure of the RLC-region of myosin with RLC and myosin heavy chain (MHC) shown in 
green and yellow, respectively. Arginine 58 is shown in van-der-Waals representation, and 
the BSR probe attached to the E-helix and putative Ca2+/Mg2+ binding site are shown in 
purple and grey, respectively. Right: OFF and ON orientations of the myosin heads with 
respect to the filament axis (FA; black arrow), reported by parallel (high value of the order 
parameter <P2>) and perpendicular (low <P2>) orientations of the E-helix probe, 
respectively. (B) <P2> measured from WT- (green) and R58Q-BSR-cRLC-E (blue) 
exchanged ventricular trabeculae in relaxing conditions (REL, pCa 9) and full calcium 
activation (ACT, pCa 4.3) at ~1.9 m sarcomere length. (C) Decrease in <P2> (<P2>) on 
calcium activation for WT- and R58Q-BSR-cRLC-E exchanged trabeculae. (D) ATPase 
activity of cardiac myofibrils in relaxing conditions and full calcium activation exchanged with 
either WT- (green) or R58Q-RLC (blue). (E) Maximum isometric force and (F) rate of force 
re-development of WT- and R58Q-BSR-cRLC-E exchanged ventricular trabeculae. Means ± 
SEM (n=4-16). Statistical significance of difference between WT and R58Q groups was 
assessed with a two-tailed unpaired Student’s t-test: *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 2. Effects of R58Q mutation on isolated cardiac myosin and RLC. (A) SDS-
PAGE of RLC-depleted porcine -cardiac myosin, and myosin reconstituted with either WT- 
and/or R58Q-RLC. The endogenous (eRLC) and recombinant RLC (rRLC) are labelled 
accordingly. (B) F-actin dependent ATPase activity of RLC-exchanged -cardiac myosins 
from (A) (for details see Materials and Methods). Data points fitted to the Michaelis-Menten 
equation (solid lines). (C) Protein stability of WT- and R58Q-RLCs were assessed by Micro-
scale Thermophoresis (MST) against increasing concentrations of Guanidine Hydrochloride 
(GdnHCl). Data points between 0 and 3 mol/L GdnHCl were fitted to a Hill equation (solid 
lines). (D) Binding of WT- and R58Q-RLC to N-terminal (C0C2) domains of cMyBP-C 
assessed by MST. Means ± SEM (n=4-6 for C0C2; n=1 for C3C5). 
 
Figure 3. R58Q perturbs the effect of sarcomere length on maximum force but not that 
on calcium sensitivity of cardiac trabeculae. Normalized (A and B) and absolute (C and D) 
force-pCa relations of WT- (A and C) and R58Q-BSR-cRLC-E (B and D) exchanged 
trabeculae at short (~1.9 m) and long (~2.2 m) sarcomere length. Force is normalized to 
maximum force at 1.9 m sarcomere length. <P2>-pCa relations for WT- and R58Q-BSR-
cRLC-E exchanged trabeculae measured in parallel with force are shown in (E) and (F), 
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respectively. Dashed and dotted lines in (B), (D) and (F) denote Hill fits for WT-BSR-cRLC-E 
exchanged trabeculae at short and long sarcomere length, respectively. Means ± SEM (n=4-
7). 
 
Figure 4. RLC phosphorylation restores myofilament function in the presence of R58Q-
RLC. (A) In vitro kinase assay of WT- and R58Q-RLC incubated without (-) and with cMLCK 
(+) and analysed by urea-glycerol PAGE. (B) In situ phosphorylation of WT- and R58Q-RLC 
exchanged into cardiac myofibrils (CMF) analysed by Phostag
TM
-SDS-PAGE and Western 
blot against RLC. (C) Time-course of phosphorylation of native, and WT- and R58Q-RLC 
exchanged CMFs. (D) Active isometric force (FActiv e) and (E) <P2> of R58Q-BSR-cRLC-E 
exchanged trabeculae before (-) and after RLC phosphorylation (+) to ~0.3 mol Pi/mol RLC 
(Fig. S6) at short sarcomere length (~1.9 m), and after RLC phosphorylation at long 
sarcomere length (~2.2 m). The values obtained for WT-BSR-cRLC-E at each sarcomere 
length are indicated by dotted lines and labelled accordingly. (F) Rate of force re–
development of R58Q-BSR-cRLC-E exchanged trabeculae before (blue) and after RLC 
phosphorylation (purple). Means ± SEM (n=4-7). Statistical significance of differences of 
values were assessed with a two-tailed paired Student’s t-test: *p<0.05, **p<0.01. 
 
Figure 5. Model for the effect of R58Q on myofilament activation in the heart. Cardiac 
contraction is controlled by regulatory structural transitions in both actin-containing thin and 
myosin-containing thick filaments. During diastole (left) both thin and thick filament are in the 
OFF state. Tropomyosin (brown lines) blocks myosin-binding sites on actin (white and grey 
circles), and myosin head domains (space filling representation, green) are sequestered on 
the surface of the thick filament backbone. During systole (right) calcium (black circle) binds 
to troponin C (red) and activates the thin filaments by removing inhibitory interactions of 
troponin I (yellow) and troponin T (purple) with actin, followed by tropomyosin moving 
azimuthally away from myosin-binding sites on actin. Calcium activation of the thin filament 
activates myosin heads through so far unknown mechanisms (indicated by vertical arrows), 
resulting in release of the heads from the surface of the thick filament to become available 
for actin binding and force-generation. The R58Q mutation in the myosin RLC (blue) reduces 
cardiac contractility by stabilizing the thick filament OFF state and preventing myosin heads 
from leaving the thick filament surface. RLC phosphorylation (+P) restores thick filament 
activation in the presence of the R58Q mutation by destabilizing the OFF state and 
promoting the myosin head ON state. Homology models for human -cardiac myosin were 
created by the Spudich laboratory (http://spudlab.stanford.edu/homology-models/). 
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Highlights 
 R58Q mutation in RLC (R58Q-RLC) promotes the myosin filament OFF state 
 R58Q-RLC reduces active force and perturbs length dependent activation (LDA) 
 Phosphorylation of R58Q-RLC restores myosin filament regulation and LDA  
 Myosin filament regulation is a target for the development of heart failure drugs 
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